Lilly Makes Billions of Weight-Loss Pills
Digest more
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...
Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
Eli Lilly (LLY) is one of Nvidia's (NVDA) many partners announced by the artificial intelligence (AI) chipmaker. The two ...
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...
Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback